Cara Therapeutics Stock Debt To Equity
| 69C Stock | EUR 4.84 0.00 0.00% |
Cara Therapeutics fundamentals help investors to digest information that contributes to Cara Therapeutics' financial success or failures. It also enables traders to predict the movement of Cara Stock. The fundamental analysis module provides a way to measure Cara Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cara Therapeutics stock.
Cara |
Cara Therapeutics Company Debt To Equity Analysis
Cara Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Cara Therapeutics Debt To Equity | 4.30 % |
Most of Cara Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cara Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Cara Therapeutics has a Debt To Equity of 4.3%. This is 91.97% lower than that of the Healthcare sector and 77.79% lower than that of the Biotechnology industry. The debt to equity for all Germany stocks is 91.17% higher than that of the company.
Cara Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cara Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cara Therapeutics could also be used in its relative valuation, which is a method of valuing Cara Therapeutics by comparing valuation metrics of similar companies.Cara Therapeutics is currently under evaluation in debt to equity category among its peers.
Cara Fundamentals
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.25) % | |||
| Operating Margin | (2.28) % | |||
| Current Valuation | 450.58 M | |||
| Shares Outstanding | 53.73 M | |||
| Shares Owned By Insiders | 16.10 % | |||
| Shares Owned By Institutions | 65.69 % | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 14.36 X | |||
| Revenue | 23.03 M | |||
| Gross Profit | (59.67 M) | |||
| EBITDA | (88.83 M) | |||
| Net Income | (88.44 M) | |||
| Cash And Equivalents | 134.45 M | |||
| Cash Per Share | 3.38 X | |||
| Total Debt | 4.99 M | |||
| Debt To Equity | 4.30 % | |||
| Current Ratio | 3.40 X | |||
| Book Value Per Share | 3.44 X | |||
| Cash Flow From Operations | (60.09 M) | |||
| Earnings Per Share | (1.50) X | |||
| Target Price | 26.33 | |||
| Number Of Employees | 84 | |||
| Beta | 0.96 | |||
| Market Capitalization | 508.24 M | |||
| Total Asset | 247.06 M | |||
| Z Score | 60.6 | |||
| Net Asset | 247.06 M |
About Cara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.